Company news

Invivyd, Inc. news in 2024

Invivyd, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights

November 13, 2024

Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor

November 13, 2024

Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to...

November 11, 2024

Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference

November 5, 2024

Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024

November 5, 2024

Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability

October 28, 2024

Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants

October 28, 2024

Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024

October 15, 2024

Invivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data

September 30, 2024

Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart)

September 22, 2024

Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19

September 11, 2024

Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™

September 3, 2024

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest

September 2, 2024

Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial

August 26, 2024

Invivyd Reports Second Quarter 2024 Financial Results and Recent Business Highlights

August 13, 2024

Invivyd to Host Conference Call Discussing Second Quarter 2024 Financial Results and Business Highlights

August 11, 2024

Invivyd Announces its Addition to the Russell 2000® and Russell 3000® Indexes

June 30, 2024

Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants

June 13, 2024

Invivyd to Participate at the Jefferies Global Healthcare Conference

June 2, 2024

Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer

May 30, 2024

Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Se...

May 30, 2024

Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC)

May 28, 2024

Invivyd Elects Two New Independent Members to its Board of Directors

May 21, 2024

Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 12, 2024

Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 8, 2024

Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback

May 6, 2024

Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights

May 1, 2024

Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position

April 29, 2024

Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™

April 14, 2024

Invivyd Announces CEO Transition

April 11, 2024

Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million

April 3, 2024

Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights

March 27, 2024

Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial

March 21, 2024

Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19

March 21, 2024

Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

February 4, 2024

Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the Pre-exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents

January 2, 2024

Calls in 2024

Decks in 2024